#Sweden #Uppsala #Beactica #BEA-28 #TEAD degrader

Beactica Therapeutics Selects BEA-28 as Preclinical Candidate

Beactica Therapeutics AB, a prominent Swedish company specializing in precision medicine, has made a significant move by selecting BEA-28 as its preclinical candidate. This decision highlights the company's strategic focus on developing advanced therapies specifically tailored for complex and aggressive tumors, particularly those that resist current treatment options.

Understanding BEA-28

BEA-28 stands out as a first-in-class small molecule that acts as a targeted degrader of TEAD transcription factors, which are crucial components of the Hippo-YAP/TAZ pathway. Unlike conventional therapeutic approaches that tend to inhibit the action of proteins, BEA-28 introduces an innovative strategy by eliminating the TEAD proteins altogether. This method is particularly advantageous for targeting cancers driven by the overactivity of this pathway, facilitating growth and contributing to treatment resistance.

In preclinical assessments, BEA-28 has exhibited promising efficacy, demonstrating significant tumor regressions at doses that are well-tolerated. Notably, it has successfully restored sensitivity to KRAS inhibitors in models that had previously shown resistance. This progress underscores the potential of biomarker-led therapeutic strategies, further enhancing the prospects for patients confronting tough-to-treat cancers.

Strengthening Beactica’s Pipeline

According to Dr. Per Källblad, the CEO of Beactica, the selection of BEA-28 reflects both the robustness of the TEAD degrader program and the confidence in the candidate's unique profile. “This compound has met all predefined success criteria for its current developmental stage, and we believe it possesses the potential to effectively treat several challenging cancers,” he stated. By advancing BEA-28 into the final candidate validation phase, Beactica aims to expedite the transition of this innovative therapy towards clinical application.

Development Criteria and Future Steps

BEA-28 was selected after successfully meeting critical benchmarks related to its chemistry, pharmacology, and absorption, distribution, metabolism, and excretion (ADME) characteristics. The next steps in the development process will include comprehensive candidate validation, which encompasses pre-GLP toxicology studies, refining the chemical manufacturing scale-up, and detailed formulation profiling. Furthermore, formal studies supporting the Investigational New Drug (IND) requirements will commence post-nomination of the candidate drug.

Unique Features of BEA-28

BEA-28, which is closely related to P65-047, has emerged as a pioneering cereblon-recruiting small molecule aimed at degrading TEAD transcription factors through the application of Beactica’s Eclipsor™ platform. By effectively shutting down the Hippo-YAP/TAZ-TEAD pathway, BEA-28 targets several mechanisms implicated in cancer growth, immune evasion, and resistance to therapies.

The compound has showcased impressive results in preclinical studies, demonstrating substantial responses among a diverse array of high-need cancer cell lineages. Additionally, it has been effective in reversing acquired resistance to KRAS inhibitor treatments within specific cellular models. In vivo, BEA-28 has proven to induce robust TEAD degradation in target tissues and promote tumor regression in xenograft models, particularly in cases such as mesothelioma and KRAS-mutant lung cancer, all observed at well-tolerated daily doses.

Beactica is progressing with the development of BEA-28 alongside a focused approach to patient selection based on specific biomarkers that predict responsiveness. Planned combination strategies include pairing this treatment with checkpoint inhibitors in high unmet need cancers, while strategizing alongside KRAS inhibitors in KRAS-driven tumor types.

Conclusion

As it stands, BEA-28 remains investigational and has not yet received global approval; hence, its safety and efficacy in human trials are still under evaluation. The ongoing efforts by Beactica Therapeutics encapsulate a significant advancement in the battle against hard-to-treat cancers, setting a hopeful precedent for future developments in precision medicine. For further details about Beactica and its initiatives, visit www.beactica.com.